Estimating Rebates and Other Discounts Received by Medicare Part D

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Healthcare Management

Background:

• Medicare Part D spending is rising, yet accurate expenditure analysis is hindered by unquantified confidential rebates and discounts.
• Existing studies face limitations in fully accounting for these financial concessions from manufacturers and pharmacies to Part D plans.

Purpose of the Study:

• To review current methodologies for estimating rebates and discounts within Medicare Part D.
• To propose an improved approach for accurately quantifying these financial concessions.

Main Methods:

• Utilized publicly available data from various governmental health agencies and oversight bodies.
• Developed and applied an analytical approach to estimate the impact of rebates and discounts on Medicare Part D spending.

Main Results:

• Estimated discounts on brand-name drugs in Medicare Part D increased from 25.4% in 2014 to 37.3% in 2018.
• Significant inter-class variations in discounts were observed, with some exceeding 50% and others remaining below 10%.
• Net prescription drug spending in Medicare Part D rose by 21% ($99B to $119B) from 2014-2018, while net spending per beneficiary remained stable (+3%).

Conclusions:

• Failure to account for increasing rebates and discounts leads to overestimations of Medicare Part D expenditures.
• Developing rigorous and transparent methods for estimating these discounts is essential for accurate spending analysis and effective cost-containment strategies.